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The molecular oscillator that drives circadian rhythmicity in mam-
mals obtains its near 24-h periodicity from posttranslational reg-
ulation of clock proteins. Activity of the major clock kinase casein
kinase I (CKI)  is regulated by inhibitory autophosphorylation.
Here we show that protein phosphatase (PP) 5 regulates the kinase
activity of CKI. We demonstrate that cryptochrome regulates
clock protein phosphorylation by modulating the effect of PP5 on
CKI. Like CKI, PP5 is expressed both in the master circadian clock
in the suprachiasmatic nuclei and in peripheral tissues independent
of the clock. Expression of a dominant-negative PP5 mutant re-
duces PER phosphorylation by CKI in vivo, and down-regulation of
PP5 significantly reduces the amplitude of circadian cycling in
cultured human fibroblasts. Collectively, these findings indicate
that PP5, CKI, and cryptochrome dynamically regulate the mam-
malian circadian clock.
circadian rhythm  period
C ircadian rhythms organize the systemic coordination of phys-iological and behavioral processes of an organism with the daily
solar cycle. The molecular oscillator that generates the clock
consists of two interconnected transcriptiontranslation feedback
loops (1, 2). The positive arm of the major feedback loop is driven
by basic helix–loop–helix–PAS (Per–Arnt–Sim) domain-containing
transcription factors CLOCK and BMAL1 (3, 4). The CLOCK
BMAL1 heterodimer activates transcription of core clock genes
cryptochrome (Cry1 and Cry2), period (Per1 and Per2), and Rev-
Erb. PER and CRY proteins translocate to the nucleus, where
they interact with CLOCKBMAL1 to down-regulate transcrip-
tion, generating the negative arm of the major feedback loop (5–7).
Posttranslational modification of clock proteins determines their
subcellular localization, intermolecular interactions, and stability
and is critical for establishing the 24-h periodicity of the clock (8, 9).
The major clock kinase casein kinase I (CKI)  and a related kinase,
CKI, regulate the negative arm of the major feedback loop
through phosphorylation of PER proteins. The importance of PER
phosphorylation is underscored by mutations in CKI kinases or
of phosphoacceptor sites in PER proteins that result in altered
circadian periods in mammals, including humans, where deviations
from normal periods manifest as sleep phase disorders (10–12).
PER phosphorylation is deregulated in the absence of crypto-
chromes, leading to constitutive nuclear localization andor deg-
radation of PER proteins, suggesting that cryptochromes modulate
PER phosphorylation and stability (2, 13).
The kinase activities of CKI and CKI are tightly regulated by
inhibitory autophosphorylation, requiring dephosphorylation of up
to eight sites for activation (14). Although serinethreonine phos-
phatases such as protein phosphatase (PP) 1, PP2A, and PP2B are
capable of activating CKI in vitro, specific physiological activa-
tors of CKI have not been identified (15). Moreover, CKI do
not appear to be maintained in an active state constitutively in vivo;
the activity of CKI in more than one pathway occurs only after
a stimulus and may rely on different phosphatases depending on the
signaling pathway or cellular context (16, 17). The role of phos-
phatases in the clock is therefore likely to be complex, because they
may be involved in stimulating CKI activity andor act in direct
opposition to clock kinases by dephosphorylating PER proteins. In
Drosophila, PP2A opposes the activity of DBT (the CKI homolog)
to stabilize PER (18), and a similar role has been proposed for an
unidentified, calyculin A-sensitive phosphatase in mammals (19).
However, the Neurospora clock is differentially regulated by two
phosphatases, homologs of PP1 and PP2A. The phosphorylation
state and stability of the core clock protein FREQUENCY (FRQ)
are different in strains containing mutants of these two phospha-
tases, although they both dephosphorylate FRQ in vitro, suggesting
that they target FRQ differently to yield dissimilar phenotypes (20).
We previously reported that human cryptochromes 1 and 2
interact with the serinethreonine phosphatase PP5 and inhibit its
activity, and we suggested that PP5 might function downstream of
cryptochrome (21). Here we show that PP5 interacts with the major
clock kinase CKI to regulate its activity both in vitro and in vivo and
that cryptochrome inhibits PP5 noncompetitively to regulate CKI
activity. Knockdown of PP5 by short hairpin RNA significantly
impairs circadian cycling in cultured cells, resulting in low-
amplitude oscillations of PER1 and PER2. Collectively, these data
indicate an important role for PP5 in the mammalian circadian
clock.
Results
PP5 Is Expressed in the Suprachiasmatic Nuclei (SCN) and Liver
Independent of the Clock. All clock proteins, including crypto-
chromes (22), are highly expressed in the master clock located in the
SCN. To determine whether PP5 colocalizes with cryptochromes in
the SCN, PP5 mRNA expression was analyzed by in situ hybrid-
ization. Although previous reports have suggested that PP5 expres-
sion is ubiquitous (23, 24), we find that PP5 mRNA is enriched in
the SCN with respect to other subcortical regions of the brain (Fig.
1A). However, unlike clock genes under the transcriptional control
of CLOCKBMAL1, such as Per1 and Per2, the level of PP5 mRNA
did not oscillate between day [Zeitgeber time (ZT) 8] and night
(ZT20) (data not shown). Similarly, when we analyzed the abun-
dance of clock proteins in the liver, we found that expression of both
PP5 and CKI was constant throughout the day (Fig. 1B). More-
over, PP5 and CKI were unaffected by the absence of both
cryptochromes, which abolishes the molecular clock and increases
expression of genes controlled by CLOCKBMAL1 (Fig. 1B, last
two lanes) (7, 8), indicating that both PP5 and CKI are expressed
independent of the clock.
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Interaction of PP5 with Core Clock Proteins. To investigate the
potential role of PP5 in the clock, we examined the interaction of
PP5 with core clock proteins by coimmunoprecipitation assay.
HEK293T cells were transfected with hemagglutinin (HA)–PP5
and the individual clock proteins, precipitated with anti-HA anti-
bodies, and probed for target proteins by Western blotting (WB)
(Fig. 2A). In agreement with previous data (21), both CRY1 and
CRY2 were precipitated by PP5. In addition, we detected an
interaction between PP5 and the clock kinase CKI. No interaction
was detected between PP5 and PER1, PER2, CLOCK, or BMAL1
under our conditions. We used the rat retinal ganglion cell line
RGC-5 (25), which expresses cryptochromes at relatively high levels
compared with most established cell lines, to investigate interac-
tions of PP5 with clock proteins under physiological conditions.
Microcystin is a microalgal toxin that binds with picomolar affinity
to the active site of the PP5 phosphatase (26, 27) and has been used
to purify endogenous PP5 by affinity chromatography (28). En-
dogenous CRY1 and CRY2 coprecipitated with PP5 (Fig. 2B);
however, we were not able to detect an interaction between
microcystin-bound PP5 and CKI. This finding may be due to one
or more factors: the PP5:CKI interaction may be more transient
and therefore harder to capture than the PP5:CRY interaction, or
microcystin binding to the active site of PP5 may preclude inter-
action with CKI.
Effect of PP5 Phosphatase Activity on Clock Protein Interactions. PP5
contains three tetratricopeptide repeat (TPR) domains in its N
terminus (Fig. 3A), which act as an autoregulatory module to inhibit
phosphatase activity (29). We previously showed that CRY and
PP5 interact through the TPR domains of PP5 (21), and we
confirmed this finding by coimmunoprecipitation of CRY2 with
His-TPR from HEK293T cells (Fig. 3B). In contrast, CKI did not
interact measurably with the PP5 TPR domains. If CKI interacts
with the catalytic site of PP5, disruption of PP5 catalytic activity
might stabilize the PP5:CKI interaction. The PP5(H304N) mutant
is catalytically inactive but maintains the normal subcellular distri-
bution of PP5 (30). We tested for quantitative differences in
protein–protein interactions by reciprocal coimmunoprecipitation
of WT or mutant PP5(H304N) with CRY2 or CKI from
HEK293T cells. Disruption of PP5 phosphatase activity had no
effect on the PP5:CRY2 interaction but increased the stability of
the PP5:CKI complex by 2-fold (Fig. 3C). Furthermore, loss of
phosphatase activity did not stabilize a previously undetected
complex with either PER protein, although both could interact with
CKI, indicating that they were properly folded (Fig. 7, which is
published as supporting information on the PNAS web site). These
data collectively suggest that the TPR domain of PP5 interacts with
Fig. 1. PP5 expression is independent of the clock. (A) In situ hybridization
was done on coronal sections of mouse brain using sense or antisense 35S-
labeled riboprobes for PP5. Double arrows indicate SCN. (B) Expression of core
clock proteins and PP5 over circadian time in mouse liver. Total protein extract
from WT and Cry1/;Cry2/ (C12) mice killed at indicated ZTs (ZT0  lights on)
was analyzed by WB with indicated antibodies.
Fig. 2. PP5 interacts with clock proteins. (A) HEK293T cells were transfected
with HA–PP5 or empty vector and the indicated FLAG- or myc-tagged clock
proteins, immunoprecipitated with anti-HA resin, and probed with antibodies
to indicated epitope tags. (B) Interaction of PP5 with endogenous clock
proteins. PP5 was precipitated from RGC-5 cell extract with microcystin-
conjugated agarose (MC) or protein A (PA) agarose (negative control) and
probed with indicated antibodies.
Fig. 3. Effect of PP5 catalytic activity on interaction with CRY2 and CKI. (A)
Schematic of PP5 protein domains. PP5 has an N-terminal autoregulatory
domain with three TPR and a C-terminal catalytic serinethreonine phospha-
tase domain (H304 is a catalytic site residue). (B) Interaction of TPR domains
with CRY2. HEK293T cells were transfected with His-PP5 TPR or empty vector
and CRY2 or CKI, immunoprecipitated with anti-His agarose, and probed
with indicated antibodies. (C) Effect of PP5 catalytic activity on interaction
with clock proteins. Protein coprecipitated with PP5(H304N) (MT; black) was
quantified by densitometry and normalized to the amount of protein inter-
acting with WT PP5 (white). (D) PP5 forms a ternary complex with CRY2 and
CKI. HEK293T cells were transfected with the indicated expression constructs,
and CRY2 precipitates were analyzed by WB to epitope tags.
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CRY and that the C-terminal catalytic domain of the phosphatase
interacts with CKI.
The interaction of CRY and CKI with distinct domains of PP5
suggested that both proteins might be able to interact with PP5 in
a ternary complex. CRY does not interact directly with CKI,
although it forms higher-order complexes with CKI in the pres-
ence of PER proteins (31). We tested for formation of a ternary
complex among CRY2, PP5, and CKI by precipitating FLAG-
CRY2 with CKI in the presence or absence of PP5 (Fig. 3D).
Significantly, CKI was detected in CRY2 precipitates only in the
presence of PP5, indicating that CRY2 and CKI can interact with
PP5 at the same time to form a stable complex.
Activation of the CKI by PP5. To determine whether PP5 acts
directly on CKI, we autophosphorylated CKI and monitored its
dephosphorylation by PP5. We incubated full-length CKI with
[-32P]ATP in the presence or absence of PP5 and monitored 32P
incorporation into CKI (Fig. 4A). Under these conditions, PP5
significantly reduced levels of CKI phosphorylation (CKI-P).
Because autophosphorylation is inversely correlated with CKI
activity (15), we asked whether PP5 dephosphorylation of CKI
would stimulate its kinase activity. As shown in Fig. 4 B and C, a
2-fold reduction in CKI-P by PP5 resulted in a similar increase in
phosphorylated casein, demonstrating that PP5 can activate CKI
kinase activity in vitro.
Cryptochrome Inhibits PP5 Activation of CKI. We analyzed whether
CRY2 could inhibit dephosphorylation of CKI by PP5 by testing
the ability of PP5 to activate CKI in the presence of CRY2. Under
our assay conditions, CRY2 inhibited the dephosphorylation of
CKI-P by PP5 up to 5-fold (Fig. 5 A and B). Whereas CRY2 alone
had no effect on CKI-P (data not shown), CRY2 inhibited
PP5-mediated dephosphorylation of CKI in a concentration-
dependent manner with an IC50 of 200 nM (Fig. 5 C and D).
Furthermore, activation of CKI by PP5 resulting in the phosphor-
ylation of PER2 was reduced in the presence of CRY2 (Fig. 5E),
demonstrating that CRY2 and PP5 can regulate the activity of
CKI toward PER2. We then performed kinetic analyses to deter-
mine the mode of inhibition of PP5 by CRY2, and we obtained
estimates of the Michaelis constant (Km) and the maximal enzyme
velocity (Vmax) for PP5 alone or in the presence of CRY2 (Fig. 5F).
Incubation with CRY2 resulted in a 2.3-fold decrease in the Vmax
of PP5 without a measurable change in Km, indicating that CRY2
is a noncompetitive inhibitor of PP5, consistent with our finding
that CRY and CKI interact with distinct regions of PP5.
Disruption of the Circadian Clock by PP5 Down-Regulation. We tested
the effect of down-regulation of PP5 on circadian cycling in
serum-shocked fibroblasts (32) using a human diploid BJ fibroblast
cell line stably transfected with a vector containing short hairpin
RNA for PP5 (33) by monitoring PER oscillation and phosphor-
ylation in whole-cell extracts. As shown in Fig. 6A, PP5 expression
was down-regulated 90% in the BJ-pSR-PP5 cell line with respect
to a control cell line without affecting protein levels of a related
phosphatase, PP1, or the CKI kinase. Serum shock induced similar
levels of PER1 and PER2 proteins in both cells lines by 6 h. In
control cells, PER1 and PER2 were predominantly hyperphospho-
rylated by 12 h, degraded, and resynthesized on a circadian time
scale at 24–30 h. However, in PP5-deficient cells we observed a
reduction in hyperphosphorylated forms of both PER proteins at all
time points and a significant decrease in the amplitude of PER
induction at 24–30 h, suggesting that clock cycling was impaired.
Because PP5(H304N) acts as a dominant negative in cells to inhibit
CKI-mediated phosphorylation of PER1 (Fig. 8, which is pub-
lished as supporting information on the PNAS web site), we believe
that this reduction in PER phosphorylation is due to decreased
CKI stimulation upon down-regulation of PP5.
We then monitored oscillation of PER1 and PER2 over a longer
period to obtain further information about cycling in the absence
of PP5. PER proteins cycled robustly in normal BJ cells, with two
circadian cycles of PER protein expression in 54 h (Fig. 6B). In
contrast, PER protein levels were significantly reduced by 12 h after
serum induction in PP5-deficient cells. Quantitative analyses of
PER protein levels show that down-regulation of PP5 decreased the
magnitude of PER oscillation from 3-fold in WT cells to 1.3-fold,
with a possible increase in period length (Fig. 6C). In summary,
these data suggest that PP5 contributes to PER phosphorylation
and stability through regulation of the primary PER kinase, CKI
(9, 34).
Discussion
Posttranslational regulation of clock proteins provides mechanisms
to regulate subcellular distribution, activity, and stability of both the
activators and repressors of the clock, giving the oscillator its stable
24-h periodicity and allowing phase adjustment by diverse external
stimuli (35). Although the role of kinases in the mammalian clock
has been fairly well studied, there are currently no data on the role
of specific phosphatases. In this article we demonstrate that PP5
interacts with the core clock proteins CRY1 and CRY2 and with
the principal clock kinase CKI and regulates CKI kinase activity.
Furthermore, down-regulation of endogenous PP5 interferes with
circadian cycling in human cells. These data suggest that PP5 is an
important component of the mammalian circadian clock.
Fig. 4. PP5 stimulates CKI activity. (A) PP5 dephosphorylates CKI. CKI was autophosphorylated with [-32P]ATP in the presence or absence of PP5. Reactions
were resolved by SDSPAGE and silver-stained, and the phosphorylation status of CKI was monitored by autoradiography. Asterisks indicate two unidentified
E. coli proteins that copurify with CKI. (B) PP5 stimulates CKI kinase activity. Autophosphorylated CKI (CKI-P) was incubated with casein in the presence or
absence of PP5; samples were removed at indicated times and resolved by SDSPAGE, followed by silver stain and autoradiography. (C) Quantitative analysis of
CKI stimulation by PP5. 32P incorporation in casein and CKI was quantified and normalized to peak phosphorylation. 32P-casein (solid lines) and 32P-CKI (dashed
lines) are shown in the presence (triangles) and absence (circles) of PP5.








Phosphorylation of PER proteins by CKI is a critical step in
execution of the negative arm of the major feedback loop; PER1
lacking CKI phosphoacceptor sites is retained in the cytoplasm,
even in the presence of cryptochromes (36). Furthermore, inhibi-
tion of CKI by chemical inhibitors interferes with normal
circadian cycling (9). Our data therefore suggest that PP5 may be
the predominant regulator of CKI function in the molecular clock,
because PP5 regulates CKI activity both in vitro and in vivo and
down-regulation of PP5 compromises circadian cycling significantly
in culture. We cannot rule out the possibility that down-regulation
of PP5 contributes in an unidentified, additional way to disruption
of clock regulation. However, the low-amplitude oscillation of
hypophosphorylated PER and possible increase in period length
observed upon down-regulation of PP5 are similar to the pheno-
types of loss-of-function kinase mutations in Neurospora (37) and
Drosophila (38) clocks, suggesting that the major role of PP5 in the
clock is regulation of CKI activity. The participation of phospha-
tases in the mammalian clock will almost certainly expand beyond
PP5, because PER proteins are also likely to be regulated by
phosphatases that directly oppose the activity of CKI (18).
Mutations affecting CKI kinase activity and phosphorylation of
PER proteins lead to multiple and conflicting phenotypes in
Drosophila and mammals (10–12, 39). This phenotypic variability
may result from the bimodal regulation of PER function by
phosphorylation, in which phosphorylation appears to be first
required for nuclear entryretention to repress transcription, but
which subsequently leads to loss of function due to degradation. We
showed that down-regulation or inhibition of PP5 by dominant-
negative phosphatase decreases phosphorylation of PER proteins
by CKI but also results in a decrease in PER stability, suggesting
a complex mode of PER regulation by CKI and PP5. Regulation
of PP5 by CRY may further contribute to the bimodal regulation
of PER; several studies have shown that PER proteins are consti-
tutively phosphorylated in the absence of cryptochromes (2, 13),
suggesting that cryptochromes function as a rheostat to control
PER phosphorylation by CKI and PP5. The detailed mechanisms
behind the bimodal regulation of PER function by phosphorylation
clearly require further study.
Although expression of most clock proteins oscillates, there are
notable exceptions (40). In particular, expression of the clock
Fig. 5. CRY2 inhibits PP5 and regulates CKI phosphorylation. (A) CRY2 inhibits PP5 activity. PP5 was preincubated with CRY2 or control buffer for 20 min; CKI-P
was added, and the reaction was incubated at 30°C. Samples were removed at indicated times and processed as in Fig. 4B. As a negative control, CRY2 was
inactivated by boiling. (B) Quantitative analysis of CRY2 inhibition. Shown is PP5 activity in the absence (circles) or presence (filled triangles) of CRY2 and in the
presence of boiled CRY2 (open triangles). (C) Effect of CRY2 concentration on PP5 activity. PP5 was incubated with increasing CRY2 before addition of CKI-P,
and reactions were analyzed at 15 min. (D) Quantitative analysis of CRY2 inhibition. Inhibition of PP5 was measured by quantifying CKI-P remaining after
treatment with CRY2 relative to PP5 alone. (E) CRY2 regulates CKI activity toward PER2. CKI-P was incubated with PER2 in the presence of PP5 or PP5 plus CRY2.
(F) CRY2 is a noncompetitive inhibitor of PP5. Rates of dephosphorylation of CKI-P (120–1,200 nM) by PP5 (100 nM) in the absence (filled circles) and the presence
(open circles) of 200 nM CRY2 are plotted in the form of a Lineweaver–Burk plot. Apparent Km and Vmax values for PP5 (with or without CRY2) were determined
by nonlinear least-squares regression of the untransformed data.
10470  www.pnas.orgcgidoi10.1073pnas.0604138103 Partch et al.
kinases and phosphatase catalytic subunits in Neurospora (20, 41),
Drosophila (18, 42), and mammals (43) is constitutive, indicating
that clock protein levels oscillate but the enzymes that modulate
their activity and stability do not. Both PP5 and CKI have
functions outside of the molecular clock, implicated in processes as
diverse as cell cycle regulation and DNA damage responses, the
Wnt-catenin pathway, and apoptotic signaling (44–47). Because
molecular circadian rhythms are intrinsic to nearly every cell in the
mammalian body, it is of considerable interest to determine
whether circadian regulation of the activity of PP5 and CKI
contributes to the function of these proteins in other pathways,
providing molecular links between the circadian cycle and its
regulation of physiological processes.
Materials and Methods
Plasmids. Human CKI was cloned into pcDNA4Bmyc-His from
pRSETB human CKI (D. Virshup, University of Utah, Salt Lake
City). hPP5 [full-length or TPR only (residues 1–179)] was ampli-
fied by RT-PCR and cloned into pcDNA4B with an HA tag; the
hPP5(H304N) mutant was generated by using the QuikChange Kit
(Stratagene). Rat PP5 in pET21a was a gift from S. Rossie (Purdue
University, West Lafayette, IN). pcDNA4B hCry1 and hCry2 were
previously described (48). mClock and mBmal1 in pBluescript
vector (J. Takahashi, Northwestern University, Evanston, IL) were
cloned into pSG5 with Flag tags. hPer1 was amplified from
HEK293T RNA by RT-PCR and cloned into pcDNA4B. pCS
hPer2 was a gift from L. Ptácek (University of California, San
Francisco). Additional constructs eliminating the His tag in
pcDNA4B CKI, Cry2, and Per1 were generated with the
QuikChange Kit. All constructs were verified by DNA sequencing.
Cell Culture and Antibodies. HEK293T cells were purchased from
American Type Culture Collection, RGC-5 cells (25) were a gift
from N. Agarwal (University of North Texas Health Science
Center, Fort Worth), and the BJ cell lines (33) were a gift from X.-F.
Wang (Duke University, Durham, NC). HEK293T and RGC-5
cells were cultured in DMEM plus 10% FBS, and BJ cells were
cultured in DMEM plus 20% FBS, under standard culture condi-
tions. The following antibodies were used: Flag (Sigma); PP5 (BD
Transduction Laboratories); myc (9E10), CKI (H-60), and PP1
(FL-18) (Santa Cruz Biotechnology); PER1, PER2, and BMAL1
(C. Lee, Florida State University, Tallahassee); and CRY1 (raised
against a C-terminal peptide of mCRY1, NSNGNGGLMGYAP-
GENVPSC). WBs were scanned and quantified by densitometry
using IMAGEQUANT 5.0 software (Molecular Dynamics).
Immunoprecipitation and Circadian Synchronization. For coimmuno-
precipitation, cells were lysed in Nonidet P-40 buffer (50 mM Tris,
pH 7.5150 mM NaCl1 mM EDTA0.5% Nonidet P-40) and
incubated with immunoaffinity resins overnight at 4°C: HA
Fig. 6. Down-regulation of PP5 disrupts circadian cycling. (A) Knockdown of endogenous PP5 decreases PER phosphorylation and impairs circadian induction
of PER protein. Circadian cycling was induced in stably transfected BJ fibroblast cultures (WT control, pSR; PP5 knockdown, pSR-PP5) by serum shock, samples
were harvested at the indicated times (hours after initiation of serum shock), and proteins were monitored by WB with indicated antibodies. Brackets show
phosphorylated species of PER proteins. NS is a nonspecific band from the PER1 antibody, used as a loading control. An asterisk indicates a nonspecific band
reacting with PER2 antibody. (B) Down-regulation of PP5 decreases the amplitude of PER protein cycling. Serum-synchronized cultures were followed for two
cycles and analyzed by WB. (C) Quantitative analysis of PER protein expression in serum-induced cultures. Circles, pSR cell line; squares, pSR-PP5 cell line.








(Roche), microcystin (Upstate Biotechnology), protein A (Invitro-
gen), Flag M2 (Sigma), or His (Santa Cruz Biotechnology). Resin
was washed three times with Nonidet P-40 buffer and eluted with
SDSPAGE sample buffer. For serum-induced cycling, BJ cells
were grown to confluence, treated with DMEM plus 50% horse
serum for 2 h (time  0 at initiation of serum shock), and
maintained in DMEM plus 0.5% FBS until harvest.
Mouse Extract Preparation and in Situ Hybridization. WT and mutant
mice (49) housed under a 12:12 h lightdark schedule were killed
at indicated ZTs (n  3; ZT0  lights on). Livers were excised,
minced, and ground in Nonidet P-40 buffer with protease
inhibitors; extracts were clarified by centrifugation for 20 min at
9,000  g at 4°C, and protein concentration was measured by
Bradford assay. For in situ hybridization of brain sections,
antisense and sense PP5 probes were generated by in vitro
transcription from pBluescript SK vector containing nucleo-
tides 846-1481 of mPP5 with T7 or T3 RNA polymerase,
respectively (Promega), in the presence of [35S]-UTP. The Per2
probe was generated, and in situ hybridizations were performed
as described (50). PP5 expression at ZT8 and ZT20 (n  3) was
analyzed by one sample t test (P  0.5).
Protein Expression and Purification. Purification of CKI (14) and
PP5 (29) from Escherichia coli and CRY2 (48) from Sf21 cells was
performed as described. Myc-PER2 was purified from transiently
transfected HEK293T cells with anti-myc (9E10) monoclonal an-
tibody prebound to protein AG agarose and washed stringently to
reduce copurifying proteins. Each protein was analyzed for purity
by SDSPAGE and silver stain, and concentration was estimated by
comparison to known protein standards.
In Vitro Kinase and Phosphatase Assays. Autophosphorylation of
CKI (CKI-P) was done in kinase buffer [25 mM Tris, pH 7.510
mM MgCl20.1 mM ATP1 Ci (1 Ci  37 GBq) of [-32P]ATP
per reaction (3,000 Cimmol, NEN Research Products)] for 30 min
at 30°C. To monitor dephosphorylation, 500 nM CKI-P was added
to 100 nM PP5 in kinase buffer (all reactions with PP5 had 10 M
palmitoyl-CoA, 2 mM MnCl2, and 1 mM iodoacetamide). Signals
were obtained on PhosphorImager screens (Molecular Dynamics)
and quantified by using IMAGEQUANT 5.0 software. Stimulation of
CKI activity was measured by adding CKI-P to either PP5 or PP5
storage buffer (20 mM Tris, pH 7.64 mM MnCl20.1% 2-
mercaptoethanol50% glycerol) in the presence of 1 g of dephos-
phorylated casein (Sigma) or 500 ng of PER2-conjugated resin.
Kinetic analyses of CRY2 inhibition were performed for 5 min at
30°C; time course experiments showed the assay was linear for up
to 15 min. CKI dephosphorylation was determined by normalizing
32P signal remaining after phosphatase treatment to the 32P signal
intensity of CKI-P before treatment.
Data Analysis. All experiments were performed three or more times.
Graphs are presented as means  standard error.
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X.-F. Wang for reagents and Y. Liu for comments. This work was
supported by National Institutes of Health Grant GM31082. C.L.P. is a
recipient of the National Institutes of Health National Research Service
Award F31 MH070151.
1. Sato, T. K., Panda, S., Miraglia, L. J., Reyes, T. M., Rudic, R. D., McNamara, P., Naik,
K. A., FitzGerald, G. A., Kay, S. A. & Hogenesch, J. B. (2004) Neuron 43, 527–537.
2. Shearman, L. P., Sriram, S., Weaver, D. R., Maywood, E. S., Chaves, I., Zheng, B.,
Kume, K., Lee, C. C., van der Horst, G. T., Hastings, M. H. & Reppert, S. M. (2000)
Science 288, 1013–1019.
3. Bunger, M. K., Wilsbacher, L. D., Moran, S. M., Clendenin, C., Radcliffe, L. A.,
Hogenesch, J. B., Simon, M. C., Takahashi, J. S. & Bradfield, C. A. (2000) Cell 103,
1009–1017.
4. Gekakis, N., Staknis, D., Nguyen, H. B., Davis, F. C., Wilsbacher, L. D., King, D. P.,
Takahashi, J. S. & Weitz, C. J. (1998) Science 280, 1564–1569.
5. Griffin, E. A., Jr., Staknis, D. & Weitz, C. J. (1999) Science 286, 768–771.
6. Kume, K., Zylka, M. J., Sriram, S., Shearman, L. P., Weaver, D. R., Jin, X.,
Maywood, E. S., Hastings, M. H. & Reppert, S. M. (1999) Cell 98, 193–205.
7. Vitaterna, M. H., Selby, C. P., Todo, T., Niwa, H., Thompson, C., Fruechte, E. M.,
Hitomi, K., Thresher, R. J., Ishikawa, T., Miyazaki, J., et al. (1999) Proc. Natl. Acad.
Sci. USA 96, 12114–12119.
8. Lee, C., Etchegaray, J. P., Cagampang, F. R., Loudon, A. S. & Reppert, S. M. (2001)
Cell 107, 855–867.
9. Miyazaki, K., Nagase, T., Mesaki, M., Narukawa, J., Ohara, O. & Ishida, N. (2004)
Biochem. J. 380, 95–103.
10. Lowrey, P. L., Shimomura, K., Antoch, M. P., Yamazaki, S., Zemenides, P. D.,
Ralph, M. R., Menaker, M. & Takahashi, J. S. (2000) Science 288, 483–492.
11. Toh, K. L., Jones, C. R., He, Y., Eide, E. J., Hinz, W. A., Virshup, D. M., Ptacek,
L. J. & Fu, Y. H. (2001) Science 291, 1040–1043.
12. Xu, Y., Padiath, Q. S., Shapiro, R. E., Jones, C. R., Wu, S. C., Saigoh, N., Saigoh,
K., Ptacek, L. J. & Fu, Y. H. (2005) Nature 434, 640–644.
13. Yagita, K., Yamaguchi, S., Tamanini, F., van Der Horst, G. T., Hoeijmakers, J. H.,
Yasui, A., Loros, J. J., Dunlap, J. C. & Okamura, H. (2000) Genes Dev. 14,
1353–1363.
14. Gietzen, K. F. & Virshup, D. M. (1999) J. Biol. Chem. 274, 32063–32070.
15. Cegielska, A., Gietzen, K. F., Rivers, A. & Virshup, D. M. (1998) J. Biol. Chem. 273,
1357–1364.
16. Liu, F., Virshup, D. M., Nairn, A. C. & Greengard, P. (2002) J. Biol. Chem. 277,
45393–45399.
17. Swiatek, W., Tsai, I. C., Klimowski, L., Pepler, A., Barnette, J., Yost, H. J. &
Virshup, D. M. (2004) J. Biol. Chem. 279, 13011–13017.
18. Sathyanarayanan, S., Zheng, X., Xiao, R. & Sehgal, A. (2004) Cell 116, 603–615.
19. Eide, E. J., Woolf, M. F., Kang, H., Woolf, P., Hurst, W., Camacho, F., Vielhaber,
E. L., Giovanni, A. & Virshup, D. M. (2005) Mol. Cell. Biol. 25, 2795–2807.
20. Yang, Y., He, Q., Cheng, P., Wrage, P., Yarden, O. & Liu, Y. (2004) Genes Dev.
18, 255–260.
21. Zhao, S. & Sancar, A. (1997) Photochem. Photobiol. 66, 727–731.
22. Miyamoto, Y. & Sancar, A. (1998) Proc. Natl. Acad. Sci. USA 95, 6097–6102.
23. Bahl, R., Bradley, K. C., Thompson, K. J., Swain, R. A., Rossie, S. & Meisel, R. L.
(2001) Brain Res. Mol. Brain Res. 90, 101–109.
24. Xu, X., Lagercrantz, J., Zickert, P., Bajalica-Lagercrantz, S. & Zetterberg, A. (1996)
Biochem. Biophys. Res. Commun. 218, 514–517.
25. Krishnamoorthy, R. R., Agarwal, P., Prasanna, G., Vopat, K., Lambert, W., Sheedlo,
H. J., Pang, I. H., Shade, D., Wordinger, R. J., Yorio, T., et al. (2001) Brain Res. Mol.
Brain Res. 86, 1–12.
26. Holmes, C. F., Maynes, J. T., Perreault, K. R., Dawson, J. F. & James, M. N. (2002)
Curr. Med. Chem. 9, 1981–1989.
27. Yang, J., Roe, S. M., Cliff, M. J., Williams, M. A., Ladbury, J. E., Cohen, P. T. &
Barford, D. (2005) EMBO J. 24, 1–10.
28. Meek, S., Morrice, N. & MacKintosh, C. (1999) FEBS Lett. 457, 494–498.
29. Sinclair, C., Borchers, C., Parker, C., Tomer, K., Charbonneau, H. & Rossie, S.
(1999) J. Biol. Chem. 274, 23666–23672.
30. Borthwick, E. B., Zeke, T., Prescott, A. R. & Cohen, P. T. (2001) FEBS Lett. 491,
279–284.
31. Akashi, M., Tsuchiya, Y., Yoshino, T. & Nishida, E. (2002) Mol. Cell. Biol. 22,
1693–1703.
32. Nagoshi, E., Saini, C., Bauer, C., Laroche, T., Naef, F. & Schibler, U. (2004) Cell
119, 693–705.
33. Zhang, J., Bao, S., Furumai, R., Kucera, K. S., Ali, A., Dean, N. M. & Wang, X. F.
(2005) Mol. Cell. Biol. 25, 9910–9919.
34. Lee, C., Weaver, D. R. & Reppert, S. M. (2004) Mol. Cell. Biol. 24, 584–594.
35. Harms, E., Kivimae, S., Young, M. W. & Saez, L. (2004) J. Biol. Rhythms 19, 361–373.
36. Takano, A., Isojima, Y. & Nagai, K. (2004) J. Biol. Chem. 279, 32578–32585.
37. Yang, Y., Cheng, P., He, Q., Wang, L. & Liu, Y. (2003) Mol. Cell. Biol. 23,
6221–6228.
38. Price, J. L., Blau, J., Rothenfluh, A., Abodeely, M., Kloss, B. & Young, M. W. (1998)
Cell 94, 83–95.
39. Preuss, F., Fan, J. Y., Kalive, M., Bao, S., Schuenemann, E., Bjes, E. S. & Price, J. L.
(2004) Mol. Cell. Biol. 24, 886–898.
40. Young, M. W. & Kay, S. A. (2001) Nat. Rev. Genet. 2, 702–715.
41. Yang, Y., Cheng, P. & Liu, Y. (2002) Genes Dev. 16, 994–1006.
42. Kloss, B., Price, J. L., Saez, L., Blau, J., Rothenfluh, A., Wesley, C. S. & Young,
M. W. (1998) Cell 94, 97–107.
43. Ishida, Y., Yagita, K., Fukuyama, T., Nishimura, M., Nagano, M., Shigeyoshi, Y.,
Yamaguchi, S., Komori, T. & Okamura, H. (2001) J. Neurosci. Res. 64, 612–616.
44. Ali, A., Zhang, J., Bao, S., Liu, I., Otterness, D., Dean, N. M., Abraham, R. T. &
Wang, X. F. (2004) Genes Dev. 18, 249–254.
45. Knippschild, U., Wolff, S., Giamas, G., Brockschmidt, C., Wittau, M., Wurl, P. U.,
Eismann, T. & Stoter, M. (2005) Onkologie 28, 508–514.
46. Morita, K., Saitoh, M., Tobiume, K., Matsuura, H., Enomoto, S., Nishitoh, H. &
Ichijo, H. (2001) EMBO J. 20, 6028–6036.
47. Urban, G., Golden, T., Aragon, I. V., Cowsert, L., Cooper, S. R., Dean, N. M. &
Honkanen, R. E. (2003) J. Biol. Chem. 278, 9747–9753.
48. Ozgur, S. & Sancar, A. (2003) Biochemistry 42, 2926–2932.
49. Selby, C. P., Thompson, C., Schmitz, T. M., Van Gelder, R. N. & Sancar, A. (2000)
Proc. Natl. Acad. Sci. USA 97, 14697–14702.
50. Thompson, C. L., Blaner, W. S., Van Gelder, R. N., Lai, K., Quadro, L., Colantuoni,
V., Gottesman, M. E. & Sancar, A. (2001) Proc. Natl. Acad. Sci. USA 98,
11708–11713.
10472  www.pnas.orgcgidoi10.1073pnas.0604138103 Partch et al.
